New developments in molecular MRD assessment in AML

The virtual AML Hub Satellite Symposium at the 46^th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Christian Thiede, Technical University of Dresden, Dresden, DE, presented the topic ‘New developments in molecular MRD assessment in AML.’

Professor Christian Thiede outlines the recently published European LeukemiaNet (ELN) Working Party recommendations for molecular assessment of MRD in AML. Then, he highlights the benefits of using next-generation sequencing (NGS) for MRD detection. Very recent developments, such as NGS of sorted cells and single cell sequencing, could represent highly sensitive and data-rich options for future molecular MRD assessment in AML.